

An Investigation into the physical chemistry of chemotherapy drugs based on copper



Saheban Khan

M.Phil, Roll No: 150020

Session: 2015-16

University Department of Chemistry

B.R.A Bihar University, Muzaffarpur

DECLARATION: I ASAN AUTHOR OF THIS PAPER / ARTICLE, HEREBY DECLARE THAT THE PAPER SUBMITTED BY ME FOR PUBLICATION IN THE JOURNAL IS COMPLETELY MY OWN GENUINE PAPER. IF ANY ISSUE REGARDING COPYRIGHT/PATENT/ OTHER REAL AUTHOR ARISES, THE PUBLISHER WILL NOT BE LEGALLY RESPONSIBLE. IF ANY OF SUCH MATTERS OCCUR PUBLISHER MAY REMOVE MY CONTENT FROM THE JOURNAL WEBSITE. FOR THE REASON OF CONTENT AMENDMENT/ OR ANY TECHNICAL ISSUE WITH NO VISIBILITY ON WEBSITE/UPDATES, I HAVE RESUBMITTED THIS PAPER FOR THE PUBLICATION. FOR ANY PUBLICATION MATTERS OR ANY INFORMATION INTENTIONALLY HIDDEN BY ME OR OTHERWISE, I SHALL BE LEGALLY RESPONSIBLE. (COMPLETE DECLARATION OF THE AUTHOR AT THE LAST PAGE OF THIS PAPER/ARTICLE

Abstract

Antiblastic chemotherapy makes substantial use of metal-based anticancer drugs. Despite its clinical application being constrained by really high poison levels and unusual medication opposition patterns, cisplatin is regarded as quite likely one of the best medications. As a result, recent years have seen a rapid expansion in the innovative work of novel metal-based anticancer drugs in order to improve clinical viability, reduce general poisonousness, and broaden the scope of action. The development of new metallodrugs other than Pt drugs with the ability to acquire intensities acting through elective components of activity has been stimulated by the variety of metal particle capabilities in science. Copper structures are perhaps interesting as anticancer experts among non-Pt substances. In fact, since many years ago, a great deal of investigations have successfully explored copper because of the suggestion that endogenous metals would be less toxic. It has been stated that the idea of ligands and contributor particles bound to the metal particle leaves the characteristics of copper-facilitated compounds in the dark. The most outstanding developments in the design and advancement of copper (I, II) structures as antitumor specialists are discussed in this assessment. The distinguishable evidence of construction movement links for the various classes of copper (I, II) buildings have received exceptional accentuation. The belief that there were no comprehensive studies of copper buildings as anticancer experts available in the writing led to the creation of this work. Additionally, despite significant efforts to combine diverse classes of copper structures, there are still little details available on the atomic foundation of the systems that underlie their antitumor effect. This outline, which compiles the key techniques used over the past ten years to create potential anticancer copper (I, II) compounds, will be helpful to the researchers working in this area.

Keywords: Copper Complexes, Compounds, Metal ion, Nanoparticles.

Introduction

Because of their distinctive chemical and physical properties, manufactured viability, low creation cost, and, in addition, because of their fundamentally significant relevance in the fields of medicine and drug science, metallic nanoparticles (NPs) and their engineered methods have attracted increasing logical interest in the field of nano-biotechnology. A few physicochemical techniques

have been developed so far on the combination of expanded types of metallic NPs. Different research domains are delving into the development and continued use of unique metallic NPs, including exploratory medicine, drug design, drug delivery, electrical and gadget creating, electrochemical sensor and biosensor advancement, horticulture science, and natural chemistry. Malignant growth is one of the most well-known medical conditions in the entire world. Modern illness treatment methods include nanoparticles in addition to their distinctive biological properties. Compared to conventional small atom pharmaceuticals and treatments, the therapeutic viability of nanoscale particles is strongly influenced by their improved receptive surface area. The ability of nano-particulate metals like gold, silver, and copper to combat cancer has so far been dynamically observed.

Copper Chemistry

Copper was first used by humans quite some time ago. According to a copper pendant discovered in Northern Iraq, copper was the primary metal known to man for about 5000 years, dating back to around 8700 BC. Since copper was largely mined on the island of Cyprus during the Roman Empire, the metal's original name was Cyprium, or "metal of Cyprus," which was later shortened to Cuprum, which gave rise to the compound symbol Cu. The Intermittent Table's 29th substance component, copper, belongs to the main group of Gathering 11 metals with electronic design. This results in the Cu (I) particle having a complete 3d¹⁰ shell and the Cu(II) particle having a partially full d-block 3d⁹ configuration operating as a normal progress metal after losing two electrons. Every single high plant and creature needs copper as a basic follow-up supplement. It is mostly found in the circulatory system of highly evolved organisms, as a cofactor in various compounds, and in copper-based hues. In a healthy 70 kg adult person, there are 8 mg in the liver, 15 mg in the heart, spleen, kidneys, mind, and blood out of a total of 80–120 mg. In any case, copper can be poisonous and, shockingly, fatal to organic beings in sufficiently high doses. Copper is incredibly toxic to bring down organic things because it is a bivalent particle. For instance, copper intensifies overall the prevention of the establishment of green growth while bacteria and other small organic entities kick the bucket in water in a copper vessel. Similar to how it can be detrimental to human cells at high fixations. It was discovered that copper binds DNA more strongly than any other

divalent cation, speeding up DNA oxidation. Proteins, polynucleotides, DNA, and bio-membranes can all have different conformational structures depending on how copper is restricted to certain locations. This restriction depends on the size of the copper atom, the preference of the charge electron, and the shape of the shaped adduct. According to reports, the $\text{Cu}^+/\text{Cu}^{2+}$ copper ions that make up blue copper proteins alter the redox potential and manipulate anomalies in electron movement. Progress metal particles, which can play out a difference in valence in redox reactions, are used in sub-atomic acknowledgment to achieve a significant level of selectivity.

Copper Homeostasis

In light of the fact that both excessive and insufficient copper accumulation can be harmful to human health, copper homeostasis is strictly regulated. The concentration of free Cu in cells at 10^{-18} M is maintained by a group of proteins known as metal restricting successions, which are conserved collections of proteins with exceptional cysteine, methionine, or histidine-rich gaps. Dietary copper is ingested by the stomach and small intestine and then reaches the bloodstream, primarily through the activity of the ATP7A protein (Menkes protein). A protein with six copper atoms in both the Cu(II) and Cu(I) form, ceruloplasmin is where the majority of the copper in ordinary human serum is bound. This structure's copper cannot be replaced. Egg whites and amino acids have the interchangeable type of copper bonded to them. The primary copper-amino corrosive compound in human serum was identified as the copper-histidine complex. Additionally, it was demonstrated that copper-histidine forms a ternary complex with human egg whites. Cu (II) is converted to Cu (I) during the take-up process by a hypothetical film-bound metalloid mechanism and is ingested by the phone through the transmembrane carriers. The 190 amino corrosive Cu carrier 1, or hCtr1, is the primary copper convergence carrier in human cells. It is mostly found in the plasma film and is primarily expressed in the liver, kidney, and heart, followed by the digestive system, with the brain and muscle having the lowest quantities. It has been suggested that hCtr1 binds copper through the amino terminal region, which is rich in methionine and histidine, and transports it across the cell membrane through pores. Competition experiments have also shown that hCtr1 is a monovalent metal carrier. In order to prevent free copper from reacting negatively with DNA, proteins, or cell membranes after entering the cytoplasm, copper

may be complexed to a variety of ligands. The majority of cytoplasmic copper is thought to be complexed to GSH as Cu, though (I). The metallothionein (MT) protein family, a group of intracellular proteins important for metal detoxification, is one example of a protein family that can receive copper from the Cu(I)-GS complex. Copper chaperones are an additional important class of atoms that are essential for the transport of copper. ATOX1 (HAH1) transports copper to the P-type ATPases ATP7A and ATP7B at the trans-Golgi organisation, COX17 transports copper to the mitochondria's cytochrome-c oxidase, and CCS1 loads copper onto the cytoplasmic turf.

Conclusion

Although copper has a long history of therapeutic use, coordination combinations of copper(I,II) have only recently been investigated as possible antiproliferative specialists, particularly since the discovery of cisplatin, the most widely used anticancer metallodrug. Copper may be less hazardous than superfluous metals like platinum because it is a crucial cofactor in many chemicals and physiological processes. Until recently, a wide range of copper structures have been tested as cytotoxic agents and found to be enhanced with an antitumor action in a few in vitro experiments (on refined malignant growth cell lines) but very few in vivo investigations (murine cancer models). According to the well-established coordination science of copper, which is occasionally improved by the adaptable Cu(I/II) redox conduct, there is actually a significant chance for the development of copper-based antiproliferative drugs that are both more potent and less dangerous. This audit has summarised advancements in this area that have been described in paper over the past ten years, starting with the genuine class of copper-TSC compounds, whose antitumor effect has been recognised since the 1960s. The overview is concluded with a section on diverse ligands that includes copper structures having polydentate Schiff base ligands, five-membered fragrant heterocycles like imidazoles, pyrazoles, and triazoles, six-membered sweet-smelling heterocycles (phen and bipy), and tertiary phosphines. The majority of the compounds under investigation fit into the category of copper(II) structures that either exhibit misshaped six-coordinate octahedral clusters or five-coordinate conditions with distorted square pyramidal and three-sided bipyramidal computations. Although the majority of these experts are mononuclear forms, dimeric compounds occasionally exhibit remarkable anticancer activity. A relatively small number of important

tetrahedral copper(I) structures with delicate tertiary phosphines or aromatic amines (such as phen, bipy) as contributing ligands have sub-micromolar antiproliferative activity. The effort made to work on copper's hydrophilic person intensifies to get a reasonable dissolvability in physiological circumstances, improving the bioavailability and reducing the in vivo harmfulness, must be mentioned among other manufactured techniques focusing on the improvement of the antitumor viability.

References

1. Fan, J.-Y.; Sun, D.; Yu, H.; Kerwin, S.M.; Hurley, L.H. Self-Assembly of a quinobenzoxazine-Mg²⁺ complex on DNA: A new paradigm for the structure of a drug-DNA complex and implications for the structure of the quinolone bacterial gyrase-DNA complex. *J. Med. Chem.*, 1995, 38(3), 408-424.
2. Wiles, J.A.; Wang, Q.; Lucien, E.; Hashimoto, A.; Song, Y.; Cheng, J.; Marlor, C.W.; Ou, Y.; Podos, S.D.; Thanassi, J.A.; Thoma, C.L.; Deshpande, M.; Pucci, M.J.; Bradbury, B.J. Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: Synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells. *Bioorg. Med. Chem. Lett.*, 2006, 16(5), 1272-1276.
3. Fang, K.C.; Chen, Y.L.; Sheu, J.Y.; Wang, T.C.; Tzeng, C.C. Synthesis, antibacterial, and cytotoxic evaluation of certain 7- substituted norfloxacin derivatives. *J. Med. Chem.*, 2000, 43(20), 3809-3812.
4. Pfeiffer, E.S.; Hiasa, H. Replacement of ParC alpha 4 helix with that of GyrA increases the stability and cytotoxicity of topoisomerase IV-quinolone-DNA ternary complexes. *Antimicrob. Agents Chemother.*, 2004, 48(2), 608-611.
5. Xia, Y.; Yang, Z.-Y.; Xia, P.; Bastow, K.F.; Tachibana, Y.; Kuo, S.-C.; Hamel, E.; Hackl, T.; Lee, K.-H. Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted 1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. *J. Med. Chem.*, 1998, 41(7), 1155-1162.
6. Kamat, A.M.; DeHaven, J.I.; Lamm, D.L. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. *Urology*, 1999, 54(1), 56-61.

7. Efthimiadou, E.K.; Thomadaki, H.; Sanakis, Y.; Raptopoulou, C.P.; Katsaros, N.; Scorilas, A.; Karaliota, A.; Psomas, G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,2'-bipyridine. *J. Inorg. Biochem.*, 2007, 101(1), 64-73.
8. Schentag, J.J. Sparfloxacin: a review. *Clin. Ther.*, 2000, 22(4), 372- 387.
9. Shingnapurkar, D.; Butcher, R.; Afrasiabi, Z.; Sinn, E.; Ahmed, F.; Sarkar, F.; Padhye, S. Neutral dimeric copper-sparfloxacin conjugate having butterfly motif with antiproliferative effects against hormone independent BT20 breast cancer cell line. *Inorg. Chem. Commun.*, 2007, 10(4), 459-462.
10. Zhou, C.-Y.; Zhao, J.; Wu, Y.-B.; Yin, C.-X.; Pin, Y. Synthesis, characterization and studies on DNA-binding of a new Cu(II) complex with N1,N8-bis(1-methyl-4-nitropyrrol-2-ylcarbonyl)triethylenetetramine. *J. Inorg. Biochem.*, 2007, 101(1), 10-18.
11. Bolos, C.A.; Papazisis, K.T.; Kortsaris, A.H.; Voyatzi, S.; Zambouli, D.; Kyriakidis, D.A. Antiproliferative activity of mixedliganddien-Cu(II) complexes with thiazole, thiazoline and imidazole derivatives. *J. Inorg. Biochem.*, 2002, 88(1), 25-36.
12. Medvetz Doug, A.; Stakleff Kimberly, D.; Schreiber, T.; Custer Paul, D.; Hindi, K.; Panzner Matthew, J.; Blanco Denise, D.; Taschner Michael, J.; Tessier Claire, A.; Youngs Wiley, J. Ovarian cancer activity of cyclic amine and thiaether metal complexes. *J. Med. Chem.*, 2007, 50(7), 1703-1706.
13. Zieba-Mizgala, A.; Puszko, A.; Regiec, A.; Kuduk-Jaworska, J. Electrophilic properties of nitroheterocyclic compounds. *Bioelectrochemistry*, 2005, 65(2), 113-119.
14. Puszko, A.; Wasylina, L.; Pelczynska, M.; Staszak, Z.; Adach, A.; Cieslak-Golonka, M.; Kubiak, M. Methyl-substituted 4-nitropyridine N-oxides as ligands: Structural, spectroscopic, magnetic and cytotoxic characteristics of copper(II) complexes. *J. Inorg. Biochem.*, 2007, 101(1), 117-126.
15. Cerecetto, H.; Gonzalez, M.; Lavaggi, M.L. Development of hypoxia selective cytotoxins for cancer treatment: an update. *Med. Chem.*, 2006, 2(3), 315-327.
16. Cerecetto, H.; Gonzalez, M. N-oxides as hypoxia selective cytotoxins. *Mini-Rev. Med. Chem.*, 2001, 1(3), 219-231.

17. Ganley, B.; Chowdhury, G.; Bhansali, J.; Daniels, J.S.; Gates, K.S. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide. *Bioorg. Med. Chem.*, 2001, 9(9), 2395-2401.
18. Urquiola, C.; Vieites, M.; Aguirre, G.; Marin, A.; Solano, B.; Arrambide, G.; Noblia, P.; Lavaggi, M.L.; Torre, M.H.; Gonzalez, M.; Monge, A.; Gambino, D.; Cerecetto, H. Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N1,N4-dioxide derivatives by complexation with vanadium. *Bioorg. Med. Chem.*, 2006, 14(16), 5503-5509.
19. Noblia, P.; Vieites, M.; Torre, M.H.; Costa-Filho, A.J.; Cerecetto, H.; Gonzalez, M.; Lavaggi, M.L.; Adachi, Y.; Sakurai, H.; Gambino, D. Novel vanadyl complexes with quinoxaline N1,N4-dioxide derivatives as potent in vitro insulin-mimetic compounds. *J. Inorg. Biochem.*, 2006, 100(2), 281-287.
20. Vieites, M.; Noblia, P.; Torre, M.H.; Cerecetto, H.; Lavaggi, M.L.; Costa-Filho, A.J.; Azqueta, A.; Lopez de Cerain, A.; Monge, A.; Parajon-Costa, B.; Gonzalez, M.; Gambino, D. Selective hypoxiacytotoxins based on vanadyl complexes with 3-aminoquinoxaline-2-carbonitrile-N 1,N 4-dioxide derivatives. *J. Inorg. Biochem.*, 2006, 100(8), 1358-1367.

Author's Declaration

I as an author of the above research paper/article, here by, declare that the content of this paper is prepared by me and if any person having copyright issue or patent or anything other wise related to the content, I shall always be legally responsible for any issue. For the reason of invisibility of my research paper on the website/amendments /updates, I have resubmitted my paper for publication on the same date. If any data or information given by me is not correct I shall always be legally responsible. With my whole responsibility legally and formally I have intimated the publisher (Publisher) that my paper has been checked by my guide (if any) or expert to make it sure that paper is technically right and there is no unaccepted plagiarism and the entire content is genuinely mine. If any issue arise related to Plagiarism / Guide Name / Educational Qualification / Designation/Address of my university/college/institution/ Structure or Formatting/ Resubmission / Submission / Copyright / Patent/ Submission for any higher degree or Job/ Primary Data/ SecondaryData Issues, I will be solely/entirely responsible for any legal issues. I informed that the most of the data from the website is invisible or shuffled or vanished from the data

basedue to some technical faultor hacking and therefore the process of resubmission is there for the scholars/students who finds trouble in getting their paper on the website. At the time of resubmission of my paper I take all the legal and formal responsibilities, If I hide or do not submit the copy of my original documents (Aadhar/Driving License/Any Identity Proofand Address Proof and Photo) in spite of demand from the publisher then my paper may be rejected or removed I website anytime and may not be consider for verification.I accept the fact that as the content of this paper and theresubmission legal responsibilities and reasons are only mine then the Publisher (Airo International Journal/Airo National Research Journal) is never responsible. I also declare thatifpublisher finds any complication or erroror anything hidden or implemented otherwise, my paper may be removed from the website or the watermark ofremark/actuality may be mentioned on my paper. Even if anything is found illegal publisher may also take legal actionagainst me

Saheban Khan